Cuban Innovations in the Fight Against Cancer

Innovative oncological treatments that are only available in Cuba provide hope and quality of life.

​

With the support of the national health system, Cuba is a place of hope for those seeking innovative treatments and positive outcomes in the fight against cancer.

 

The fact that there are treatments that extend the life expectancy of individuals with cancer and offer the possibility of healing provides comfort and hope to those experiencing this difficult phase of life.

 

Cuban Medical Services offers these patients proven combination therapies that have been developed in Cuba. This includes the therapeutic vaccines CIMAvax-EGF® and Vaxira®, as well as the monoclonal antibodies CIMAher® (Nimotuzumab) and HeberFERON®. These therapies have been successfully developed by researchers from the biotechnology sector and the Cuban National Institute of Oncology and Radiobiology (INOR), which conducts clinical studies.

 

Examples of Applications: New Insights into Non-Small Cell Lung Cancer (CIMAvax-EGF® and Vaxira®).  

 

Cuba offers groundbreaking therapies for advanced non-small cell lung cancer (Stage IIIB and IV). This includes the therapeutic vaccine CIMAvax-EGF®, which acts on the epidermal growth factor receptor and is also well tolerated by older patients.

 

Additionally, Vaxira® is also designed to combat this illness in advanced stages and shows an objective clinical response to the disease with very few side effects following chemotherapy. Patients must have completed the first stage of cancer treatment at least four weeks prior and be in a stable condition. The effectiveness of Vaxira® is supported by evidence of tumor growth control.

 

Both therapies contribute to improving respiratory function, physical condition, and emotional well-being of patients. They are conducted in two phases:

 

Induction: A higher dose is administered.

Maintenance Therapy: The maintenance therapy is conducted with intermittent dosing in accordance with relevant medical guidelines.

 

Example Application: Head and Neck Tumors (Esophageal Cancer)  

 

CIMAher®: The comprehensive oncological treatment with CIMAher® represents a promising alternative in advanced head and neck cancer. This monoclonal antibody has proven effective in combination with conventional therapies such as radiotherapy and chemotherapy and has led to favorable outcomes in disease control. It is also used for malignant tumors of the esophagus and in patients with non-small cell lung cancer.

 

Example Application: Basal Cell Carcinoma (Skin Cancer)  

HeberFERON®: HeberFERON®, a medication that combines recombinant human alpha and gamma interferon, provides hope for patients with basal cell carcinoma (skin cancer). The monoclonal antibody can be used for lesions of any size and location, even in high-risk areas like the H-zone of the face or in locally advanced tumors which are difficult to treat due to their proximity to the eyes or brain.

 

It extends the effect of treatment by at least five years, reduces the occurrence of new lesions by eight times, and decreases tumor mass, thereby preventing complex surgeries on the face and delicate body parts and their consequences. These highly specialized oncological treatments present a unique opportunity that Cuba offers to those seeking hope and an improved quality of life. With the support of the national health system, Cuba positions itself as a destination for those seeking innovative treatments and positive outcomes in the fight against cancer.

 

Please contact us for inquiries regarding treatments and therapies.